Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542552 | 0.84 | APLNR (0.53) | ADRA1ATAAR1HTR2AHTR2CAOC3 | |
| SCHEMBL7332987 | 0.82 | ADRA1A (0.62) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A | |
| SCHEMBL681333 | 0.80 | ADRA1A (0.64) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A | |
| SCHEMBL5267466 | 0.79 | ADRA1A (0.62) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A | |
| SCHEMBL2470010 | 0.79 | MTNR1A (0.59) | TAAR1MTNR1AMTNR1B | |
| SCHEMBL15757833 | 0.78 | ADRA1A (0.57) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A | |
| SCHEMBL18183442 | 0.77 | MTNR1B (0.84) | MTNR1AMTNR1BHTR2C | |
| SCHEMBL27002039 | 0.77 | MTNR1A (0.66) | ADRA1ATAAR1MTNR1AMTNR1BHSD17B10 | |
| SCHEMBL8867858 | 0.76 | ADRA1A (0.68) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A | |
| SCHEMBL20153915 | 0.76 | ADRA1A (0.58) | ADRA1ATAAR1MTNR1AMTNR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | ADRA1A 38/4885TAAR1 121/4885MTNR1A 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.